Lu Ke, Jing Zhou, Wenjian Mao, Tao Chen, Yin Zhu, Xinting Pan, Hong Mei, Vikesh Singh, James Buxbaum, Gordon Doig, Chengjian He, Weili Gu, Weihua Lu, Shumin Tu, Haibin Ni, Guoxiu Zhang, Xiangyang Zhao, Junli Sun, Weiwei Chen, Jingchun Song, Min Shao, Jianfeng Tu, Liang Xia, Wenhua He, Qingyun Zhu, Kang Li, Hongyi Yao, Jingyi Wu, Long Fu, Wendi Jiang, He Zhang, Jiajia Lin, Baiqiang Li, Zhihui Tong, John Windsor, Yuxiu Liu, Weiqin Li
PURPOSE: Infected pancreatic necrosis (IPN) is a highly morbid complication of acute necrotising pancreatitis (ANP). Since there is evidence of early-onset immunosuppression in acute pancreatitis, immune enhancement may be a therapeutic option. This trial aimed to evaluate whether early immune-enhancing Thymosin alpha 1 (Tα1) treatment reduces the incidence of IPN in patients with predicted severe ANP. METHODS: We conducted a multicentre, double-blind, randomised, placebo-controlled trial involving ANP patients with an Acute Physiology and Chronic Health Evaluation II (APACHE II) score ≥ 8 and a computed tomography (CT) severity score ≥ 5 admitted within 7 days of the advent of symptoms...
July 2022: Intensive Care Medicine